Aclaris Therapeutics Inc (NAS:ACRS)
$ 4.07 0.25 (6.54%) Market Cap: 290.72 Mil Enterprise Value: 172.04 Mil PE Ratio: 0 PB Ratio: 2.23 GF Score: 72/100

Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 11:00AM GMT
Release Date Price: $17.29 (+6.40%)
Boobalan Pachaiyappan
H.C. Wainwright & Co. - Analyst

Good morning and good afternoon, everyone. And thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Boobalan Pachaiyappan. I'm H.C. Wainwright Vice President and Senior Analyst. With me today is Dr. Neal Walker, Co-Founder, Director, and CEO of Aclaris Therapeutics. Aclaris is focused on developing novel drugs for immuno-inflammatory diseases.

Neal, the floor is yours.

Neal Walker
Aclaris Therapeutics, Inc. - Co-Founder, CEO, & Director

Thank you. And thank you for having us. I'm Dr. Neal Walker. I'm the CEO of Aclaris. I'll be walking through an overview of the company for you today. So, Aclaris is a development-stage biotechnology company focused on the kinome and the development of small molecule therapeutics for immuno-inflammatory diseases. We have three key components to the company: the people -- we have a world-class ex-Pfizer kinase leadership with decades of experience looking at the kinome; we also have the KINect platform, which

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot